Thursday, 20 Sep 2018

News

U.S. News 2018-19 Rheumatology Rankings

The Annual U.S. News and World Report Rankings of Hospitals has listed the top contenders in the field of rheumatology. The U.S. News Review rates hospitals nationwide in 16 specialties – including rheumatology. Of the 4,500 hospitals covered by U.S. News that were analyzed, 158 were classified nationally in at least one specialty area.

Success of Stopping Depends on the Biologic

The type of biologic disease-modifying anti-rheumatic drug (DMARD) being used and remission duration were important factors predicting whether remission was maintained among patients with rheumatoid arthritis after cessation of the biologic, a Japanese study found.

Cardiovascular Benefits of Maintaining Biologic Therapy

An Australian prospective study of patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) has shown that sustained use of tumour necrosis factor (TNFi) inhibitors or biologics can reduce the risks of cardiovascular events (CVEs).

The RheumNow Week in Review – No Good Gout (8.10.18)

Dr. Jack Cush reviews the news and latest journal articles from the past week on RheumNow.com. Info on Surgery and Hip Fractures, Gout drugs abandoned, Allopurinol escalation, hydroxychloroquine drug levels, how to treat scleroderma in India and exactly who gets back pain.

Fractures Augment 10 Year Mortality Risks

This nationwide study of adults (50+ yrs) from Denmark has shown that following a fragility fracture, the 10-years mortality risk was increased, especially in the first year following the fracture. 

Early Hip Fracture Surgery Reduces Mortality

CMAJ reports that seniors are more likely to survive a hip fracture if the surgery is done as soon as they’re admitted to the hospital - suggesting hospitals should expedite operating room access for patients whose surgery has already been delayed for nonmedical reasons. (Citation source: bit.ly/2KzdrCt) 

Dr. Roland Moskowitz (1929 - 2018)

Dr. Roland Moskowitz was a giant in the rheumatology world for decades, and one of a handful of researchers who doggedly rose to one of rheumatology's greatest challenge: osteoarthritis. He has passed away at the age 88 years.

Selective Use of HLA-B*5801 Testing in Gout

The current edition of JAMA Internal Medicine describes an Asian gout patient who presents with an allopurinol hypersensitivity reaction that could have been diagnosed by testing for HLA-B*5801.

Febuxostat (IR or XR) Effective in Gout with Renal Impairment

Saag and colleagues report the results of a 3 month phase III trial demonstrating equal efficacy between febuxostat extended release (XR) and immediate release (IR) formulations in patients with gout.  and normal or impaired renal function.

Big Advances for Two Osteoporosis Drugs

New developments with the FDA and new scientific findings are adding momentum to two drugs experts believe are game-changers in osteoporosis treatment.

In May, the FDA approved denosumab (Prolia) for use in patients who have glucocorticoid-induced osteoporosis and are at high risk of fracture. 

Back Pain in Psoriatic Arthritis

A single center study of psoriatic arthritis patients has shown that rheumatologist-judged inflammatory back pain (IBP) and criteria defining IBP may not perform well when ascertaining axial involvement in PsA patients. 

Higher Infection Rates for Infliximab in Psoriasis

A prospective study of psoriasis patients from the British Association of Dermatologists Biologic Interventions Register demonstrated that infliximab therapy yielded 2-3 times more serious infection than seen in those treated with non-biologic DMARDs or methotrexate (MTX).